Leaders and experts from Hong Kong Hospital Authority visited Shenzhen Cell Valley for exchange and visit
On December 16 morning, the hospital authority of the Hong Kong special administrative region office comprehensive clinical services, senior administrative manager, Dr Xie Da clinical services manager ms OuKun Ye, hospital authority senior pharmacist lady Yang and Mary university of Hong Kong hospital blood internal medicine consultant doctor Chen Shouren doctor, the Chinese university of Hong Kong prince of Wells hospital blood internal medicine consultant doctor shao-ming wang doctor, Hong Kong queen Elizabeth hospital blood internal medicine consultant doctor Liu Shimin line to Shenzhen cell valley communication. Professor Shi Yuanyuan, chairman of our company, Professor Wang Jianxun, chief scientist, Wei Zheng, commercial director, Fu Yuchen, assistant to the chairman, Sun Rui, minister of Marketing Department, and Wang Lu, director of general Office warmly received the company.
Visitors in the chairman of the history of digital wisdom of Shenzhen cell valley exhibition hall, GMP research and development production laboratory and quality management laboratory visited, the field learned about the latest research achievements in the field of Shenzhen cell therapy and laboratory layout, and the valley of Shenzhen cell enterprise culture has a deep understanding and understanding.
Chairman Shi Yuanyuan first comprehensively introduced the core advantages of Shenzhen Cell Valley, Including the underlying technology of cell therapy, the virus vector and the industrial production technology of cell preparation, Core assets- -a team of r & d and production talents trained by the two founders, Clinical application aspects, Shenzhen Cell Valley has carried out substantial and comprehensive cooperation with a number of hospitals, To date, CAR-T cell products targeting GMP grades targeting BCMA, CD19, CD19 / CD22, CD7, CD38, Treating more than 100 cases of multiple myeloma, lymphoma and leukemia, The success rate of autologous CAR T cells in patients was 100%. For patients who failed to get the previous treatment and showed relapse or resistance, the clinical treatment efficiency rate after CAR-T cell therapy is up to 78%.
Chairman Shi Yuanyuan introduced to the Hong Kong guests that Shenzhen Cell Valley has set up a wholly-owned subsidiary, —— Hong Kong Cell Valley Biomedical Co., Ltd., in Hong Kong, to provide more convenient services for the cooperation with Hong Kong hospitals and enterprises in the future. In the second half of this year, Shenzhen Cell Valley declared the entry and exit of special goods to Shenzhen Customs, and successfully passed the risk assessment of virus vector product report,
At the same time, it also participated in the "white list" and positive goods list identification of the entry-exit biomedical special goods pilot enterprises (institutions) in Shenzhen. In view of the recent special policies in the field of CGT issued by three ministries and commissions in the Guangdong Free Trade Zone, Shenzhen Cell Valley is preparing a medical service institution in Qianhai Free Trade Zone, so as to make full use of the national policies to help the development of cell therapy industry in Shenzhen and Hong Kong.
Dr Xie da of Shenzhen cell valley of strategic development planning, master the core technology and clinical case expressed a high degree of recognition, and introduces the public medical management institutions of the Hong Kong special administrative region, the Hong Kong hospital authority of the Hong Kong special administrative region, direct management of all public hospitals and the relevant medical institutions. At present, CAR T-T cell therapy in Hong Kong public hospitals began in May 2021. There are three CAR T-cell therapy centers located in Mary Hospital, Prince of Wells Hospital and Hong Kong Children's Hospital. So far, more than 100 patients have been treated. With the increase in the number of available products and the clinical demand for unregistered indications, Hong Kong is actively exploring the introduction of more products to meet the needs, while considering the introduction of mainland products, actively seeking to expand the scope of CAR-T cell therapy services, and considering referring patients to the mainland for CAR-T treatment and cooperation. Dr. Wang Shaoming, Dr. Chen Shouren and Dr. Liu Shimin also expressed a high recognition of the advantages of Shenzhen Cell Valley in the quality control of cell preparation, and the recent virus vector cooperation and future cell preparation center.
Dr. Xie presented a letter of thanks to the Hong Kong Medical Authority to Chairman Shi
